Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Vertical Diplopia
Semin Neurol 20:21-30, Acierno,M.D., 2000
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Neurologic Manifestations of SLE 1972
Nebraska State Journ Med, Oct 1972, pp 395., Aita,J., 1972
The Face of Myasthenia Gravis
Neurol 95:89-90, Ruiter, A.M.,et al, 2020
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Differential Diagnosis of Finger Drop
Neurologist 19:128-131, Varatharaj, A.,et al, 2015
Juvenile Myasthenia Gravis: Recommendations for Diagnostic Approaches and Treatment
Neuropediatrics 45:75-83, Marina, A.D.,et al, 2014
Binocular Vertical Diplopia
Mayo Clin Proc 73:55-66, Brazis,P.W.&Lee,A.G., 1998
Pure Motor Hand Weakness
Semin Neurol 16:75-81, Lewis,R.A., 1996
Abnormalities of Eyelid Closure
In Walsh & Hoyt's Clinical Neuro-ophthalmology, Williams & Wilkins, Baltimore, 2:967, Miller,M.R., 1985
Retraction of the Lower Eyelid
Neurol 29:386-389, Cohen,M.M.,et al, 1979
Clinical Pathological Conference
Giant-cell Arteritis of Temporal Artery (temporal arteritis) , Case Record 35-1977, NEJM 297:4927., , 1977
Electrodiagnosis Studies in Neuromuscular Disease
NEJM 285:1244, Samaha,F., 1971
Hippus, In System of Ophthalmology
(Ed) , Vol 12 Neuro-ophthalmology C. V. Mosby Company 1971, p 637., Duke-Elder,W.S., 1971
Ocular Myopathy
Arch Neurol 20:1, Magora,A.,et al, 1969
A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Two Cases of Congenital Myasthenic Syndrome with Vocal Cord Paralysis
Neurol 84:1281-1282, Al-Shahoumi, R.,et al, 2015
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Tempo of Disease. In Merritts Neurology. Signs and symptoms in neurologic diagnosis: Approach to the patient
, Rowland, L.P.,et al, 2009
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Dysphagia as the Sole Manisfestation of Myasthenia Gravis
JNNP 76:1297-1300, Llabrs,M.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Difference in Distribution of Muscle Weakness Between Myasthenia Gravis and the Lambert-Eaton Myasthenic Syndrome
JNNP 73:766-768, Wirtz,P.W.,et al, 2002
Antiphospholipid Syndrome and Multiple Ischemic Strokes in a Patient with Myasthenia Gravis
Kurume Med J 49:211-216, Kaji, M.,et al, 2002
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340, LeForestier,N.,et al, 1995
Congenital Myasthenic Syndromes
In:Neurologic Clinics, 12:401-4371994., Engel,A.G., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Differential Diagnosis of Guillain-Barre Synd, In Guillain-Barre Synd
Thieme Med Publ, Ch 3, p 42993., Parry,G.J., 1993
Ocular Myasthenia Gravis
J Natl Med Assoc 85:681-684, March,G.A.&Johnson,J.N., 1993
Chronic Limb-Girdle Myasthenia Gravis
Neurol 42:1153-1156, Oh,S.J.&Kuruoglu,R., 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992